Primary prevention of acute renal failure in the critically ill

Current Opinion in Critical Care

Volumn 11, Issue 6, 2005, Pages 537-541

  Kellum, John A ^a   Leblanc, Martine ^b   Gibney, R T Noel ^c   Tumlin, James ^d   Lieberthal, Wilfred ^e   Ronco, Claudio ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d EMORY UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

Acute renal failure; Acute tubular necrosis; Kidney; Prevention; Radio contrast

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR STIMULATING AGENT; ALBUMIN; ANTIINFLAMMATORY AGENT; ATRIAL NATRIURETIC FACTOR; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CREATININE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; GELATIN; GROWTH FACTOR; HETASTARCH; ISOTONIC SOLUTION; LAZAROID; LOOP DIURETIC AGENT; MANNITOL; NORADRENALIN; PROSTAGLANDIN DERIVATIVE; SODIUM CHLORIDE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TOXIN; UNINDEXED DRUG; URODILATIN; VASOPRESSIN;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; FLUID THERAPY; GLOMERULUS FILTRATION; HEMOFILTRATION; HUMAN; HYDRATION; HYPOTENSION; IMMUNE DEFICIENCY; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY DISEASE; MULTIPLE ORGAN FAILURE; REVIEW; RISK FACTOR; SEPTIC SHOCK; SHOCK; SURVIVAL; TACHYCARDIA;

CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE, ACUTE; UNITED STATES;

EID: 28144442266     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000179934.76152.02     Document Type: Review

References (47)

1. Mueller C, Buerkle G, Buettner HJ. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-336.
2. Trivedi HS, Moore H, Nasr S. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29-C34.
3. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328-2334. A small but interesting study showing that bicarbonate-based fluids may be more effective than chloride-based fluids in preventing contrast nephropathy.
4. Finfer S, Bellomo R, Boyce N, et al., SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256. A large (7000 patients) RCT showing no difference between 0.9% saline and albumin for fluid resuscitation in the ICU.
5. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of HES and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357:911-916.
6. Hager B. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schwiez Med Wochenschr 1996; 126:666-673.
7. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420.
8. Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11:97-104.
9. Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care 1997; 1:53-59.
10. Ip-Yam PC, Murphy S, Baines M. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 1994; 78:842-847.
11. Homsi E, Barreiro MF, Orlando JM, Higa EM. Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997; 19:283-288.
12. Beall AC, Holman MR, Morris GC. Mannitol-induced osmotic diuresis during vascular surgery. Arch Surg 1963; 86:34-42.
13. Gubern JM, Sancho JJ, Simo J. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988; 103:39-44.
14. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31:674-680.
15. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in ATN. Auriculin Anaritide ARF Study Group. N Engl J Med 1997; 336:828-833.
16. Lewis J, Salem MM, Chertow GM. Atrial natriuretic factor in oliguric acute renal failure. Am J Kidney Dis 2000; 36:767-774.
17. Meyer M, Pfarr E, Schirmer G. Therapeutic use of natriuretic peptide ularitide in acute renal failure. Ren Fail 1999; 21:85-100.
18. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310-1315. A small (n = 61) provocative study suggesting a possible beneficial effect of ANP on the risk of ARF.
19. Kellum JA, Decker JM. The use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29:1526-1531.
20. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002; 28:877-883.
21. Australian and New Zealand Intensive Care Society Clinical Trials Group. A multicenter, randomized, double-blind, placebo-controlled trial of low-dose dopamine in critically ill patients with early renal dysfunction. Lancet 2000; 356:2139-2143.
22. Tumlin JA, Wang A, Murray PT. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143:894-903.
23. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005; 46:26-34. A RCT comparing fenoldopam to placebo for prevention of ARF, showing no benefit.
24. Stone GW, McCullough PA, Tumlin JA, et al., CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290:2284-2291.
25. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45:1425-1431.
26. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998; 11:151-156.
27. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999; 14:1064-1066.
28. Kramer BK, Preuner J, Ebenburger A, et al. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant 2002; 17:910-915.
29. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362:598-603.
30. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 15:1454-1458.
31. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43:1-9.
32. Pannu N, Manns B, Lee H, Tonnelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65:1336-1374.
33. Genet S, Kale RK, Baquer NZ. Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem 2000; 210:23-28.
34. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-410. An important study in healthy humans suggesting that N-acetylcysteine may reduce serum creatine without improving GFR.
35. Bellomo R, Goldsmith D, Uchino S, et al. Prospective controlled trial of effect of medical emergency team on postoperative morbidity and mortality rates. Crit Care Med 2004; 32:916-921.
36. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826-1831.
37. Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28:2758-2765.
38. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999; 159:1186-1192.
39. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23:282-287.
40. Van den Berghe G, de Zegher F, Vlasselaers D, et al. Thyrotropin- releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med 1996; 24:590-595.
41. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279-1282.
42. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
43. Gold J, Cullinane S, Chen J, et al. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000; 85:506-508.
44. Prielipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. New Horiz 1995; 3:456-468.
45. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367.
46. Frank H, Werner D, Lorusso V, et al. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60:176-182.
47. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340.